Literature DB >> 15189948

Prolonged nitric oxide inhalation fails to regress hypoxic vascular remodeling in rat lung.

Bao Hua Jiang1, Junko Maruyama, Ayumu Yokochi, Manabu Iwasaki, Homare Amano, Yoshihide Mitani, Kazuo Maruyama.   

Abstract

STUDY
OBJECTIVE: The purpose of present study was to investigate whether long-term nitric oxide (NO) inhalation during the recovery in air might improve the regression of chronic hypoxic pulmonary hypertension (PH) and vascular changes.
MATERIALS AND METHODS: The rats were exposed to 10 ppm of NO in air for 10 days (n = 12) and 30 days (n = 4), or 40 ppm of NO in air for 10 days (n = 6) and 30 days (n = 12) following 10 days of hypobaric hypoxia (380 mm Hg, 10% oxygen). For each NO group, air control rats following hypoxic exposure were studied at the same time (n = 13, 11, 9, and 11, respectively). Normal air rats (n = 6) without hypoxic exposure and rats (n = 7) following 10 days of hypoxic exposure were used as normal and chronic hypoxic control groups, respectively. Muscularization of normally nonmuscular peripheral arteries and medial hypertrophy of normally muscular arteries were assessed by light microscopy. An additional 16 rats were used to investigate the recovery of pulmonary artery pressure with (n = 8) and without NO inhalation (n = 8) after 10 days of hypobaric hypoxia.
RESULTS: Long-term hypoxia-induced PH, right ventricular hypertrophy (RVH), and hypertensive pulmonary vascular changes, each of which regressed partly after recovery in room air. There were no differences among rats with and without NO during each recovery period in RVH, medial wall thickness of muscular artery, and the percentages of muscularized arteries at the alveolar wall and duct levels. Continuous inhaled 40 ppm NO decreased pulmonary artery pressure from 40.1 +/- 1.1 to 29.9 +/- 3.8 mm Hg (mean +/- SE) [n = 8], which was not different in the rats without NO inhalation (n = 8). Urine nitrate level was higher in rats that had inhaled NO.
CONCLUSION: Continuous NO inhalation showed no effect on regression of pulmonary vascular remodeling in chronic hypoxic PH after returning to room air.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15189948     DOI: 10.1378/chest.125.6.2247

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Early exposure to hyperoxia or hypoxia adversely impacts cardiopulmonary development.

Authors:  Manimaran Ramani; Wayne E Bradley; Louis J Dell'Italia; Namasivayam Ambalavanan
Journal:  Am J Respir Cell Mol Biol       Date:  2015-05       Impact factor: 6.914

2.  Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension.

Authors:  Yasuharu Yamada; Junko Maruyama; Erquan Zhang; Amphone Okada; Ayumu Yokochi; Hirofumi Sawada; Yoshihide Mitani; Tatsuya Hayashi; Koji Suzuki; Kazuo Maruyama
Journal:  J Anesth       Date:  2013-07-02       Impact factor: 2.078

3.  Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

Authors:  Liliana Moreno-Vinasco; Mardi Gomberg-Maitland; Michael L Maitland; Ankit A Desai; Patrick A Singleton; Saad Sammani; Lee Sam; Yang Liu; Aliya N Husain; Roberto M Lang; Mark J Ratain; Yves A Lussier; Joe G N Garcia
Journal:  Physiol Genomics       Date:  2008-02-26       Impact factor: 3.107

4.  Potential contribution of phenotypically modulated smooth muscle cells and related inflammation in the development of experimental obstructive pulmonary vasculopathy in rats.

Authors:  Shoichiro Otsuki; Hirofumi Sawada; Noriko Yodoya; Tsutomu Shinohara; Taichi Kato; Hiroyuki Ohashi; Erquan Zhang; Kyoko Imanaka-Yoshida; Hideto Shimpo; Kazuo Maruyama; Yoshihiro Komada; Yoshihide Mitani
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

5.  Formulation, preclinical and clinical evaluation of a new submicronic arginine respiratory fluid for treatment of chronic obstructive pulmonary disorder.

Authors:  Virendra Pratap Singh Rathor; Pradeep Chugh; Rashid Ali; Anuj Bhatnagar; Syed Ehtaishamul Haque; Aseem Bhatnagar; Gaurav Mittal
Journal:  Saudi Pharm J       Date:  2015-03-20       Impact factor: 4.330

Review 6.  Oxidative Stress and Its Implications in the Right Ventricular Remodeling Secondary to Pulmonary Hypertension.

Authors:  Matthew Mikhael; Christian Makar; Amir Wissa; Trixie Le; Mansoureh Eghbali; Soban Umar
Journal:  Front Physiol       Date:  2019-09-24       Impact factor: 4.566

7.  Lung damage created by high tidal volume ventilation in rats with monocrotaline-induced pulmonary hypertension.

Authors:  Masako Kawai; Erquan Zhang; Jane Chanda Kabwe; Amphone Okada; Junko Maruyama; Hirofumi Sawada; Kazuo Maruyama
Journal:  BMC Pulm Med       Date:  2022-03-05       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.